Browsing by Issue Date, starting with "2025-02-26"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Validation and psychometric properties of the portuguese version of the Freiburg Mindfulness Inventory (FMI)Publication . Iacob, Vivien; Carmo, Cláudia; Garcês, Soraia; Chiodelli, Roberto; Walach, Harald; Neves de Jesus, SaúlThis research aimed to develop a Portuguese version of the Freiburg Mindfulness Inventory (FMI) short form and investigate its psychometric properties through two complementary studies. The first study included a sample of 337 participants. It analyzed the scale's internal consistency, reliability, and factorial validity by conducting an exploratory and confirmatory factor analysis using a randomly divided sample of the general population. The second study examined the convergent and concurrent validity, temporal stability, and sensitivity to change in the FMI among participants in an Interculturality and Mindfulness program (n = 150). The results indicated high internal consistency and reliability for the Portuguese version of FMI (omega = 0.87). The exploratory and confirmatory factor analysis reinforced the instrument's unidimensional solution. The findings supported the convergent and concurrent validity, temporal stability, and sensitivity to change. The translated version's psychometric qualities are satisfactory and can be used to assess mindfulness in the Portuguese population.
- Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis: challenges and opportunitiesPublication . Marques da Silva, Barbara Sofia; Bragança, JoséThe potential of induced pluripotent stem cells (iPSCs) for modeling and treating metabolic associated fatty liver disease (MAFLD) and metabolic associated steatohepatitis (MASH) is emerging. MAFLD is a growing global health concern, currently with limited treatment options. While primary mesenchymal stem cells hold promise, iPSCs offer a versatile alternative due to their ability to differentiate into various cell types, including iPSC-derived mesenchymal stem cells. However, challenges remain, including optimizing differentiation protocols, ensuring cell safety, and addressing potential tumorigenicity risks. In addition, iPSCs offer the possibility to generate complex cellular models, including three-dimensional organoid models, which are closer representations of the human disease than animal models. Those models would also be valuable for drug discovery and personalized medicine approaches. Overall, iPSCs and their derivatives offer new perspectives for advancing MAFLD/MASH research and developing novel therapeutic strategies. Further research is needed to overcome current limitations and translate this potential into effective clinical applications.